The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies

Figures & data

Figure 1. Overview of the FAST study. Reproduced with permission²⁷.

Figure 2. ALL-HEART study overview. In total, 5,215 patients aged over 60 years with ischemic heart disease will be randomized to receive allopurinol or no additional therapy, in addition to their usual care, then followed up for an expected average of 4 years for outcomes. Reproduced with permission¹⁹.

Figure 3. Flow diagram of the FEATHER study. Reproduced with permission²⁸.

MacDonald TM, Ford I, Nuki G, et al. Protocol of the febuxostat versus allopurinol streamlined trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open 2014;4:e005354

 PubMed Web of Science ®Google Scholar

Mackenzie IS, Ford I, Walker A, et al., on behalf of the ALL-HEART study group. A multi-centre, prospective, randomised, open-label, blinded endpoint trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALLHEART study. BMJ Open 2016;6:e013774

 PubMed Web of Science ®Google Scholar

Hosoya T, Kimura K, Itoh S, et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials 2014;15:26

 PubMed Web of Science ®Google Scholar